286 related articles for article (PubMed ID: 28419645)
21. Information feedback of
Mu Y; Gui J; Lang Z; Ren C; Yan L; Liu H; Liang J; Feng H
J Infect Public Health; 2020 Sep; 13(9):1336-1341. PubMed ID: 31289004
[TBL] [Abstract][Full Text] [Related]
22. Computed DWI MRI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer Than That of Actual DWI, STIR Imaging, and FDG-PET/CT.
Ohno Y; Yui M; Takenaka D; Yoshikawa T; Koyama H; Kassai Y; Yamamoto K; Oshima Y; Hamabuchi N; Hanamatsu S; Obama Y; Ueda T; Ikeda H; Hattori H; Murayama K; Toyama H
J Magn Reson Imaging; 2023 Jan; 57(1):259-272. PubMed ID: 35753082
[TBL] [Abstract][Full Text] [Related]
23. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
24. Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer.
Usuda K; Funazaki A; Maeda R; Sekimura A; Motono N; Matoba M; Uramoto H
Ann Thorac Cardiovasc Surg; 2017 Dec; 23(6):275-280. PubMed ID: 28978865
[TBL] [Abstract][Full Text] [Related]
25. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
[TBL] [Abstract][Full Text] [Related]
26. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
[TBL] [Abstract][Full Text] [Related]
27. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
Deuschl C; Nensa F; Grueneisen J; Poeppel TD; Sawicki LM; Heusch P; Gramsch C; Mönninghoff C; Quick HH; Forsting M; Umutlu L; Schlamann M
Acta Radiol; 2017 Aug; 58(8):991-996. PubMed ID: 28273734
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
30. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
[No Abstract] [Full Text] [Related]
31. Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.
Seki S; Fujisawa Y; Yui M; Kishida Y; Koyama H; Ohyu S; Sugihara N; Yoshikawa T; Ohno Y
Magn Reson Med Sci; 2020 Feb; 19(1):29-39. PubMed ID: 30880291
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
33. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
34. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
[TBL] [Abstract][Full Text] [Related]
36. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
38. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection?
Buchbender C; Hartung-Knemeyer V; Beiderwellen K; Heusch P; Kühl H; Lauenstein TC; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):877-82. PubMed ID: 23428414
[TBL] [Abstract][Full Text] [Related]
39. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
40. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Kotani Y; Nishimura Y; Higashino T; Sugimura K
J Magn Reson Imaging; 2007 Sep; 26(3):498-509. PubMed ID: 17729341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
